{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:50Z","timestamp":1790697890110,"version":"4.1.0"},"reference-count":8,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To describe a case of severe bilateral granulomatous uveitis caused by treatment with faricimab.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A single case was reviewed.\n                    <jats:bold>Results:<\/jats:bold>\n                    A 79-year-old woman with diabetic macular edema developed severe uveitis OU 16 days after bilateral intravitreal (IVT) injections of faricimab. The patient\u2019s visual acuity (VA) was hand motions OD and 20\/400 OS. She refused IVT antibiotics at bedside but consented to an emergency pars plana vitrectomy (PPV) OU. The laboratory workup for infectious and autoimmune etiologies was unremarkable, as were bacterial and fungal cultures from the PPV. High-dose systemic steroids were initiated after surgery. The patient\u2019s VA recovered to 20\/30 OD and 20\/25 OS.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Reports of severe uveitis resulting from injections of faricimab have been documented. We describe a unique case in which the patient with granulomatous uveitis OU experienced a significant decline in vision. With high-dose systemic steroid therapy and surgical intervention, her VA recovered to near baseline.\n                  <\/jats:p>","DOI":"10.1177\/24741264251330339","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T12:21:41Z","timestamp":1745238101000},"page":"494-497","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Bilateral Sterile Granulomatous Uveitis Caused by Intravitreal Injections of Faricimab"],"prefix":"10.1177","volume":"9","author":[{"given":"Christine","family":"Hill","sequence":"first","affiliation":[{"name":"Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Arhontoulis","sequence":"additional","affiliation":[{"name":"Medical Scientist Training Program, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen","family":"Bui","sequence":"additional","affiliation":[{"name":"Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"DeVaro","sequence":"additional","affiliation":[{"name":"Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-4880","authenticated-orcid":false,"given":"Peter H.","family":"Tang","sequence":"additional","affiliation":[{"name":"Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26074"},{"issue":"1","key":"e_1_3_2_3_2","article-title":"Diabetic macular edema management: a review of anti-vascular endothelial growth factor (VEGF) therapies","volume":"16","author":"Cheema AA","year":"2024","unstructured":"Cheema AA, Cheema HR. Diabetic macular edema management: a review of anti-vascular endothelial growth factor (VEGF) therapies. Cureus. 2024;16(1):e52676. doi:10.7759\/cureus.52676","journal-title":"Cureus"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10050981"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.08.008"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0530"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2293925"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000001527"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251330339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251330339","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251330339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:52Z","timestamp":1790695552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251330339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/24741264251330339"],"URL":"https:\/\/doi.org\/10.1177\/24741264251330339","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}